Shree Ganesh Biotech (India) Ltd (SHREEGANES) fair value: what the stock is really worth
We calculate from audited financials what Shree Ganesh Biotech (India) Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
Compare price with fair valuebelow fair value = cheap, above = expensive
Check the quality50 and up solid, 75 and up strong
Watch it or check another stockalert when fair value or trend changes
Basic Materials · IN · Market cap ₹199M (≈ $2.1M) · ISIN INE051N01026
A solid business, but trading 219% above our fair value of ₹0.1600.
As of Aug 26, 2026, the fair value of Shree Ganesh Biotech (India) Ltd is ₹0.1600 per share against a price of ₹0.5100, so the fair value sits 69% below the price. A model estimate from reported figures, not an analyst target.
!Weak Growth (revenue 5y −22.0 %/yr)
!Loss over the last twelve months · -10.4% net margin · fiscal year 2026 7.6%
!Low debt · negative free cash flow
!Trails peers (3/10)
!Narrow moat 15/100
!Evidence only low, so the estimate is less certain
!Weak on future: 17 out of 100
!Weak on past: 2 out of 100
Evidence: LowRange ₹0.1200 to ₹0.2000
Fair value as of: Aug 26, 2026
From 7 valuation models · updated 14 days ago
Share price −5.6% over the past month.
This is the short version. In the app for Shree Ganesh Biotech (India) Ltd:
Watch Shree Ganesh Biotech (India) Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceable See the method →
What matters now
The price sits above even our optimistic bull case (₹0.2000). The favourable scenario is already priced in.
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 26, 2026.
How to read this chart
60‑month range ₹0.4800 – ₹9.64 · fair‑value band ₹0.1200 – ₹0.2000 · the ₹0.5100 price screens above the ₹0.1600 fair value. Dashed = 300-day average. As of Aug 26, 2026.
Shree Ganesh Biotech (India) Ltd (SHREEGANES) currently trades at ₹0.5100, while our model-based Fair Value estimate is ₹0.1600, implying the stock looks roughly 218.8% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Basic Materials sector. Bull case: the Asset-Based group reads highest at a median of ₹1.07 per share, and 2 of the 7 models we run sit above the ₹0.5100 price. Bear case: the Earnings-Based group reads lowest at ₹0.1000, and 5 of the 7 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Shree Ganesh Biotech (India) Ltd generated revenue of ₹49.7M at a net margin of 7.6%. Revenue declined 29.4% year over year. It earns a return on equity of 0.6%. Net debt stands at ₹1.7M. Fundamentals as of Aug 26, 2026
Scenario range: ₹0.1200 (bear) to ₹0.2000 (bull), the price of ₹0.5100 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 41% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at 9% fair-value upside, at −69%, SHREEGANES screens richer than that median.
Fair Value models
Based on fiscal year 2026 figures (about 5 months old). Earnings retained since then (₹0.0044 per share) are deliberately not added.
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Highest evidence
Residual Income best evidence₹0.9700₹0.8500₹0.510070
Growth-Adj P/E₹0.1100₹0.1600₹0.200068
Graham-Dodd₹0.0600₹0.1000₹0.120067
All 7 models by family
Earnings-Based
Graham-Dodd₹0.0600₹0.1000₹0.120067
Multiples
P/E Multiple₹0.1600₹0.2100₹0.260063
P/S Multiple₹0.1200₹0.1600₹0.200058
P/B Multiple₹0.1200₹0.1600₹0.200055
Asset-Based
NCAV (Graham)₹0.8000₹1.07₹1.6054
Economic Profit
Residual Income best evidence₹0.9700₹0.8500₹0.510070
Growth Earnings
Growth-Adj P/E₹0.1100₹0.1600₹0.200068
Widest divergence: Asset-Based (₹1.07) versus Earnings-Based (₹0.1000). Highest evidence: Residual Income (70).
Notify me when SHREEGANES reaches fair value
Put SHREEGANES on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
P/E ratio56.0as of Jul 6, 2026
P/S ratio4.25P/E × margin
EPS (TTM)₹−0.0100price ÷ EPS = P/E 56.0
Net margin7.6%FY2026
Return on equity0.6%TTM
Return on assets (EBIT)0.6%avg 5y
More key figures
Profitability
Operating margin−62.5%TTM
Growth
Revenue (TTM)₹50.2MTTM
Revenue growth (YoY)+3.3%3y avg −57.0%
EPS growth (YoY)−51.4%
Balance sheet & cash flow
Free cash flow−₹82.0MFY2026
Net debt₹1.7MFY2021
Figures from reported company fundamentals · as of Aug 26, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality52/100
Of which business quality 52
· Market factors (momentum, volatility) 29
Profitability16
Margins and returns on capital today
Quality Growth34
Are margins and returns improving?
Cashflow33
Earnings quality: real cash, not paper profit
Fin. Strength75
Balance sheet, leverage, solvency risk
Investment99
Disciplined investing over empire-building
Low Volatility66
Calm price path (market factor)
Momentum19
Price trend over the last 3–12 months (market factor)
52W Momentum2
Distance to the 52-week high (market factor)
Net Issuance82
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Shree Ganesh Bio-Tech (India) Limited engages in plant tissue culture activities in India. The company trades seeds and bhushi. It also engages in production, processing, and marketing of hybrid seeds for various crops, including corn, sunflower, cotton, paddy, grain, and sorghum. The company was incorporated in 1982 and is based in Kolkata, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Shree Ganesh Biotech (India) Ltd reported revenue of ₹49.7M in FY2026 versus ₹726M in FY2022, a compound −48.9%/yr. Reported net income was ₹3.8M in FY2026, compounding −37.8%/yr from FY2022.
Growth Quality 14/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2026)
₹49.7M
Latest YoY
−78.3%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−57.0%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−22.0%
Avg. revenue growth/yr (7Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−2.3%
Value creation/yr (5Y, in INR) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.6%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+3.6%
Dividend yield0.0%
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9.6% (2020) → −19.3% (2026) · falling
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
This stockSector peers
VALUE0· sector 20
FUTURE17· sector 45
PAST2· sector 25
HEALTH100· sector 97
DIVIDEND0· sector 39
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Aug 26, 2026).
Is Shree Ganesh Biotech (India) Ltd (SHREEGANES) overvalued or undervalued?
As of Aug 26, 2026, our model estimates a fair value of ₹0.1600 versus a price of ₹0.5100, about −69% upside (overvalued).
What is the fair value of SHREEGANES?
Our model-based fair value for Shree Ganesh Biotech (India) Ltd is ₹0.1600 (as of Aug 26, 2026), built from audited fundamentals. The current price: ₹0.5100.
What is the quality score of SHREEGANES?
Shree Ganesh Biotech (India) Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Our model-based price target is the fair value of ₹0.1600 (as of Aug 26, 2026) from 7 valuation models. Cautious scenario ₹0.1200, optimistic scenario ₹0.2000. It is a calculation from audited fundamentals, not an analyst target.
What is the Shree Ganesh Biotech (India) Ltd stock forecast for 2026?
Our models put fair value at ₹0.1600, about −69% upside versus a price of ₹0.5100 (overvalued). Cautious scenario ₹0.1200, optimistic scenario ₹0.2000. The calculation is refreshed regularly with new filings.
What is the revenue of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Shree Ganesh Biotech (India) Ltd reported trailing-twelve-month revenue of about ₹49.7M (latest available figure, as of Aug 26, 2026).
What is the net profit margin of SHREEGANES?
The net profit margin of Shree Ganesh Biotech (India) Ltd is about 7.6%, meaning it keeps roughly 7.6% of revenue as net income. Based on the latest reported figures.
What is the intrinsic value of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shree Ganesh Biotech (India) Ltd it is ₹0.1600 per share (as of Aug 26, 2026), against a price of ₹0.5100. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Shree Ganesh Biotech (India) Ltd stock overvalued or undervalued in 2026?
As of Aug 26, 2026, SHREEGANES trades above its calculated fair value: price ₹0.5100, fair value ₹0.1600, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SHREEGANES?
No. The price is what the market pays today (₹0.5100); the fair value is what the company's own numbers justify (₹0.1600). For Shree Ganesh Biotech (India) Ltd the two are ₹0.3500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shree Ganesh Biotech (India) Ltd worth?
The market values Shree Ganesh Biotech (India) Ltd at about ₹199M (market capitalisation, as of Aug 26, 2026). Per share that is ₹0.5100; our models calculate a fair value of ₹0.1600 per share.
What do the bullish and bearish scenarios say about SHREEGANES?
Our models span a range for Shree Ganesh Biotech (India) Ltd: cautious scenario ₹0.1200, base ₹0.1600, optimistic ₹0.2000 per share (as of Aug 26, 2026, price ₹0.5100). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SHREEGANES?
Shree Ganesh Biotech (India) Ltd trades at a price-to-earnings ratio of 56.0 (as of Aug 26, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹0.1600 is built from several models across several years. Other multiples: P/S 0.0.
How solid is the balance sheet of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Balance-sheet figures for Shree Ganesh Biotech (India) Ltd (as of Aug 26, 2026): return on equity 0.6%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is SHREEGANES from its 52-week high?
Shree Ganesh Biotech (India) Ltd trades at ₹0.5100, about 41% below its 52-week high of ₹0.8600 (as of Aug 26, 2026). Distance from the high says nothing about value: that is what the fair value of ₹0.1600 is for.
Which stocks are comparable to Shree Ganesh Biotech (India) Ltd?
From the same area (Basic Materials) we also value Corteva, Inc, Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shree Ganesh Biotech (India) Ltd stock attractive at the current price?
The data as of Aug 26, 2026: price ₹0.5100, calculated fair value ₹0.1600 (−69%), Quality Score 52/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SHREEGANES calculated?
We run Shree Ganesh Biotech (India) Ltd through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹0.1600, with the spread shown as a cautious and an optimistic scenario.
Free · no account needed
Watch Shree Ganesh Biotech (India) Ltd in the live analysis
One click puts Shree Ganesh Biotech (India) Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
